Observing the effects of proton therapy in lymphoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to document the effectiveness and side effects of proton radiotherapy in patients with mediastinal lymphoma. It focuses on reducing therapy-associated toxicity, particularly in young patients who are at risk for long-term complications from conventional radiation methods. By utilizing modern radiation techniques like proton therapy, the study seeks to minimize radiation exposure to critical organs such as the heart and lungs. Data collected will help inform future treatment planning and feasibility for this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Histologically confirmed lymphoma according to WHO

* Patient consent
* Patient age ≥18 years.
* Presence of the need for mediastinal radiotherapy and the presumed benefit of mediastinal radiotherapy using protons in comparison to photon radiation (e.g. improved heart, lungs, and breast protection compared to photon radiation).
* Ability of the patient to give consent

Exclusion Criteria:

Age \<18 years

* Non-consent of the patient to the disclosure of his data
* Cancellation of the patient's participation in the study

Where it's running

• University Hospital Heidelberg
  Heidelberg, Germany Recruiting

Study contacts

• Principal investigator: Laila König, MD — University Hospital Heidelberg
• Study coordinator: Laila König, MD
• Email: laila.könig@med.uni-heidelberg.de
• Phone: +49 6221

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Proton Therapy for Mediastinal Lymphoma in Denmark

  This study tests whether using proton therapy for mediastinal lymphoma can lower late-toxicity risk compared with photon therapy in adults.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen, Select A State · NCT07817641

• Memory-Enhanced CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests memory-enhanced 7×19-THEMIS CAR-T cells in adults with relapsed or refractory large B-cell lymphoma to see how safe they are and whether tumors shrink or disappear.

  Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07788118

• TC011 (CD19 CAR-T) for relapsed or refractory large B‑cell lymphoma

  This will test a CD19-targeted CAR-T therapy called TC011 in adults whose large B‑cell lymphoma has relapsed or not responded after prior treatments.

  Recruiting Phase 1/2 TICAROS Co., Ltd. · Seoul, Seoul · NCT07473167

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Treatment of relapsed large B-cell lymphoma with WZTL-002 CAR T-cells

  This study is testing a new CAR T-cell therapy called WZTL-002 to see if it can help adults with relapsed large B-cell lymphoma that hasn't worked with standard chemotherapy.

  Recruiting at 3 sites Phase 2 Malaghan Institute of Medical Research · Auckland, Auckland and 2 other locations · NCT06486051

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.